

Biosimilars in Ontario

UPDATED: August 24, 2021

For up-to-date information on Limited Use codes and indications, [click here](#)

Molecule	Company	Indications	LU
Adalimumab			
Amgevita	Amgen	RA pJIA PsA AS PsO Uveitis (Adult & Pediatric)	600 601 602 603 609 611
Idacio	Fresenius Kabi	RA pJIA PsA AS PsO Uveitis (Adult & Pediatric)	600 601 602 603 609 611
Hadlima	Merck	RA pJIA PsA AS PsO Uveitis (Adult & Pediatric)	600 601 602 603 609 611
Hulio	Viartis (BGP)	RA pJIA PsA AS PsO Uveitis (Adult & Pediatric)	600 601 602 603 609 611
Hyrimoz	Sandoz	RA pJIA PsA AS PsO Uveitis (Adult Only)	600 601 602 603 609 612

Molecule	Company	Indications	LU
Etanercept			
Brenzys	Merck	RA AS PsA JIA PsO	499 498 563 514 591
Erelzi	Sandoz	RA AS pJIA PsA	512 513 514 563
Infliximab			
Avsola	Amgen	RA AS PsA PsO	592 593 594 595
Inflectra	Pfizer	RA AS PsA	468 469 470
Renflexis	Merck	RA AS PsA	541 542 543
Rituximab			
Truxima	Teva	RA initial RA renewal GPA/MPA initial GPS/MPA renewal	575 576 587 588
Riximyo	Sandoz	RA initial RA renewal GPA initial MPA initial	581 582 616 617
Ruxience	Pfizer	RA initial RA renewal GPA/MPA initial GPS/MPA renewal	583 584 585 586